Firdapse (amifampridine phosphate) is an oral voltage-gated potassium channel inhibitor for the symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. Firdapse increases the release of acetylcholine from nerve cells, prolonging the depolarization of the pre-synaptic cell membrane and allowing for enhanced calcium influx into the neuron. This, in turn, facilitates increased release of acetylcholine and improves neuromuscular transmission.

If you have a Hayes login, click here to view the full report on the Knowledge Center.